Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 17,841 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Anticholinergic Toxicity
Interventions: Rivastigmine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 10 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions: AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B); Drug · Other
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Chula Vista, California • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Plaque Psoriasis
Interventions: AUR101, Placebo; Drug
Lead sponsor: Aurigene Discovery Technologies Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 19 more

Conditions: Pulmonary Sarcoidosis
Interventions: OATD-01, Placebo; Drug
Lead sponsor: Molecure S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Obesity
Interventions: Acceptance and Commitment Therapy-Based Physical Activity Intervention, Physical Activity Education Control; Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Depression
Interventions: EVT 101, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Oceanside, California • San Diego, California • Tampa, Florida + 11 more

Conditions: Hematologic Malignancy
Interventions: Baseline Geriatric Screening/Assessment, Geriatrician Co-Management; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 75 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type1 Diabetes
Interventions: CGM Academy; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Macular Degeneration
Interventions: 0.5 mg ranibizumab; Drug
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more

Conditions: Accidental Fall
Interventions: Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency; Behavioral
Lead sponsor: National Opinion Research Center; Other
Eligibility: 65 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Reflexology; Other
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Chicago, Illinois • Flint, Michigan • Grand Rapids, Michigan + 5 more

Conditions: Gastrointestinal Dysmotility
Interventions: Saline Solution for Injection, Ipamorelin; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more

Conditions: Heart Failure, Chronic Heart Failure
Interventions: Heartfelt Device installed, Standard care, Heartfelt-guided care, Questionnaires; Device · Other
Lead sponsor: Heartfelt Technologies; Industry
Eligibility: 22 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Little Rock, Arkansas • Hackensack, New Jersey • Bala-Cynwyd, Pennsylvania

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Traumatic Brain Injury
Interventions: PNT001, %5 dextrose for infusion; Biological
Lead sponsor: Pinteon Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colon Cancer, Lung Cancer, Prostate Cancer
Interventions: Contact Intervention; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: HIV Infections
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more

Conditions: Autism Spectrum Disorder
Interventions: Education communication skills (ECS) training, Partners in School; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Atrial Fibrillation
Interventions: Amiodarone, DC-cardioversion, Rate Control; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more

Conditions: Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions: Eye exam; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes
Interventions: AZD1656, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Essential Tremor, Parkinson Disease, Dystonia
Interventions: Active biphasic pulse stimulation---Home Settings, Active biphasic pulse stimulation---VIN Biphasic, Active biphasic pulse stimulation---Stimulator Off; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Distal Radius Fracture
Interventions: Standardized Preoperative Education, Standard of care, Preoperative and postoperative questionnaires; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Rivastigmine for Antimuscarinic Delirium

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Patient-Centered Care for the Older Adult With Hematologic Malignancy

CGM Academy for Youth With Type 1 Diabetes

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Evaluating the Cost Effectiveness of STEADI

Home-Based Symptom Management Via Reflexology for Breast Cancer Patients

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

The HEARTFELT Study

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

Partners in School: Promoting Continuity Across Home and School

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Physiology, Imaging and Modeling of Essential Tremor

Preoperative Education in Hand and Wrist Surgery